Response Under 37 CFR 1.116
Expedited Procedure
Examining Group 1617
Application No. 10/056,680
Amendment Dated: January 9, 2007
Reply to Final Office Action of July 11, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition comprising:

(a) ~~at least one~~ 0.1 to 1000 milligrams of a sterol absorption represented by Formula (II):



(II)

or pharmaceutically acceptable salts or solvates thereof;



~~(I)~~

~~or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (I) or of the isomers thereof, wherein:~~

~~Ar^1 and Ar^2 are independently selected from the group consisting of aryl and R^4-substituted aryl;~~

~~Ar^3 is aryl or R^5 substituted aryl;~~

~~X, Y and Z are independently selected from the group consisting of $-CH_2-$, -CH(lower alkyl)- and -C(dilower alkyl)-;~~

~~R and R^2 are independently selected from the group consisting of OR^6, $O(CO)R^6$, $O(CO)OR^9$ and $O(CO)NR^6R^7$;~~

~~R^1 and R^3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;~~

~~q is 0 or 1;~~

~~r is 0 or 1;~~

~~m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;~~

~~R^4 is 1-5 substituents independently selected from the group consisting of lower alkyl, OR^6, $O(CO)R^6$, $O(CO)OR^9$, $O(CH_2)_{1-5}OR^6$, $O(CO)NR^6R^7$, NR^6R^7, $NR^6(CO)R^7$, $NR^6(CO)OR^9$, $NR^6(CO)NR^7R^8$, $NR^6SO_2R^9$, $COOR^6$, $CONR^6R^7$, COR^6, $SO_2NR^6R^7$, $S(O)_{0-2}R^9$, $O(CH_2)_{1-10}COOR^6$, $O(CH_2)_{1-10}CONR^6R^7$, (lower alkylene)$COOR^6$, $CH=CH-COOR^6$, CF_3, CN, NO_2 and halogen;~~

~~R^5 is 1-5 substituents independently selected from the group consisting of OR^6, $O(CO)R^6$, $O(CO)OR^9$, $O(CH_2)_{1-5}OR^6$, $O(CO)NR^6R^7$, NR^6R^7, $NR^6(CO)R^7$, $NR^6(CO)OR^9$, $NR^6(CO)NR^7R^8$, $NR^6SO_2R^9$, $COOR^6$, $CONR^6R^7$, COR^6, $SO_2NR^6R^7$, $S(O)_{0-2}R^9$, $O(CH_2)_{1-10}COOR^6$, $O(CH_2)_{1-10}CONR^6R^7$, (lower alkylene)$COOR^6$ and $CH=CH-COOR^6$;~~

~~R^6, R^7 and R^8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and~~

~~R^9 is lower alkyl, aryl or aryl-substituted lower alkyl;~~ and

(b) 1 to 1000 milligrams of aspirin.

2. (Canceled).

3. (Canceled).

4. (Withdrawn) The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (III):



(III)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (III) or of the isomers thereof, or prodrugs of the compounds of Formula (III) or of the isomers, salts or solvates thereof, wherein, in Formula (III) above:

Ar^1 is R^3-substituted aryl;

Ar^2 is R^4-substituted aryl;

Ar^3 is R^5-substituted aryl;

Y and Z are independently selected from the group consisting of $-CH_2-$, -CH(lower alkyl)- and -C(dilower alkyl)-;

A is selected from -O-, -S-, -S(O)- or $-S(O)_2-$;

R^1 is selected from the group consisting of $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$ and

$-O(CO)NR^6R^7$; R^2 is selected from the group consisting of hydrogen, lower alkyl and aryl; or R^1 and R^2 together are =O;

q is 1, 2 or 3;

p is 0, 1, 2, 3 or 4;

R^5 is 1-3 substituents independently selected from the group consisting of $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^9$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2$-lower alkyl, $-NR^6SO_2$-aryl, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $S(O)_{0-2}$-alkyl, $S(O)_{0-2}$-aryl, $-O(CH_2)_{1-10}-COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, o-halogeno, m-halogeno, o-lower alkyl, m-lower alkyl, -(lower alkylene)-$COOR^6$, and

$-CH=CH-COOR^6$;

R^3 and R^4 are independently 1-3 substituents independently selected from the group consisting of R^5, hydrogen, p-lower alkyl, aryl, $-NO_2$, $-CF_3$ and p-halogeno;

R^6, R^7 and R^8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and

R^9 is lower alkyl, aryl or aryl-substituted lower alkyl.

5. (Withdrawn) The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (IV):



(IV)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (IV) or of the isomers thereof, or prodrugs of the compounds of Formula (IV) or of the isomers, salts or solvates thereof, wherein, in Formula (IV) above:

A is selected from the group consisting of R^2-substituted heterocycloalkyl, R^2-substituted heteroaryl, R^2-substituted benzofused heterocycloalkyl, and R^2-substituted benzofused heteroaryl;

Ar^1 is aryl or R^3-substituted aryl;

Ar^2 is aryl or R^4-substituted aryl;

Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the spiro group  ; and

R^1 is selected from the group consisting of:

$-(CH_2)_q-$, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;

$-(CH_2)_e-G-(CH_2)_r-$, wherein G is -O-, -C(O)-, phenylene, $-NR^8-$ or $-S(O)_{0-2}-$, e is 0-5 and r is 0-5, provided that the sum of e and r is 1-6;

$-(C_2-C_6$ alkenylene)-; and

$-(CH_2)_f-V-(CH_2)_g-$, wherein V is C_3-C_6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;

R^5 is selected from:

 ;

R^6 and R^7 are independently selected from the group consisting of $-CH_2-$, $-CH(C_1-C_6$ alkyl)-, -C(di-(C_1-C_6) alkyl), -CH=CH- and

-C(C_1-C_6 alkyl)=CH-; or R^5 together with an adjacent R^6, or R^5 together with an adjacent R^7, form a -CH=CH- or a -CH=C(C_1-C_6 alkyl)- group;

a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R^6 is -CH=CH- or -C(C_1-C_6 alkyl)=CH-, a is 1; provided that when R^7 is -CH=CH- or -C(C_1-C_6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R^6's can be the same or different; and provided that when b is 2 or 3, the R^7's can be the same or different;

and when Q is a bond, R^1 also can be selected from:



where M is -O-, -S-, -S(O)- or -S($O)_2$-;

X, Y and Z are independently selected from the group consisting of -CH_2-, -CH(C_1-C_6 alkyl)- and -C(di-(C_1-C_6) alkyl);

R^{10} and R^{12} are independently selected from the group consisting of -OR^{14}, -O(CO)R^{14}, -O(CO)OR^{16} and -O(CO)$NR^{14}R^{15}$;

R^{11} and R^{13} are independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl and aryl; or R^{10} and R^{11} together are =O, or R^{12} and R^{13} together are =O;

d is 1, 2 or 3;

h is 0, 1, 2, 3 or 4;

s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4; provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6; provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;

v is 0 or 1;

j and k are independently 1-5, provided that the sum of j, k and v is 1-5;

R^2 is 1-3 substituents on the ring carbon atoms selected from the group consisting of hydrogen, $(C_1$-$C_{10})$alkyl, $(C_2$-$C_{10})$alkenyl, $(C_2$-$C_{10})$alkynyl, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkenyl, R^{17}-substituted aryl, R^{17}-substituted benzyl, R^{17}-substituted benzyloxy, R^{17}-substituted aryloxy, halogeno, $-NR^{14}R^{15}$, $NR^{14}R^{15}(C_1$-C_6 alkylene)-, $NR^{14}R^{15}C(O)(C_1$-C_6 alkylene)-, $-NHC(O)R^{16}$, OH, C_1-C_6 alkoxy, $-OC(O)R^{16}$, $-COR^{14}$, hydroxy$(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy$(C_1$-$C_6)$alkyl, NO_2, $-S(O)_{0\text{-}2}R^{16}$, $-SO_2NR^{14}R^{15}$ and $-(C_1$-C_6 alkylene$)COOR^{14}$; when R^2 is a substituent on a heterocycloalkyl ring, R^2 is as defined, or is =O or  ; and, where R^2 is a substituent on a substitutable ring nitrogen, it is hydrogen, $(C_1$-$C_6)$alkyl, aryl, $(C_1$-$C_6)$alkoxy, aryloxy, $(C_1$-$C_6)$alkylcarbonyl, arylcarbonyl, hydroxy, $-(CH_2)_{1\text{-}6}CONR^{18}R^{18}$,



wherein J is -O-, -NH-, $-NR^{18}$- or $-CH_2$-;

R^3 and R^4 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of $(C_1$-$C_6)$alkyl, $-OR^{14}$, $-O(CO)R^{14}$, $-O(CO)OR^{16}$, $-O(CH_2)_{1\text{-}5}OR^{14}$, $-O(CO)NR^{14}R^{15}$, $-NR^{14}R^{15}$, $-NR^{14}(CO)R^{15}$, $-NR^{14}(CO)OR^{16}$, $-NR^{14}(CO)NR^{15}R^{19}$, $-NR^{14}SO_2R^{16}$, $-COOR^{14}$, $-CONR^{14}R^{15}$, $-COR^{14}$, $-SO_2NR^{14}R^{15}$, $S(O)_{0\text{-}2}R^{16}$, $-O(CH_2)_{1\text{-}10}$-$COOR^{14}$, $-O(CH_2)_{1\text{-}10}CONR^{14}R^{15}$, $-(C_1$-C_6 alkylene$)$-$COOR^{14}$, $-CH{=}CH$-$COOR^{14}$, $-CF_3$, -CN, $-NO_2$ and halogen;

R^8 is hydrogen, $(C_1$-$C_6)$alkyl, aryl $(C_1$-$C_6)$alkyl, $-C(O)R^{14}$ or $-COOR^{14}$;

R^9 and R^{17} are independently 1-3 groups independently selected from the group consisting of hydrogen, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, -COOH, NO_2, $-NR^{14}R^{15}$, OH and halogeno;

R^{14} and R^{15} are independently selected from the group consisting of hydrogen, $(C_1$-$C_6)$alkyl, aryl and aryl-substituted $(C_1$-$C_6)$alkyl;

R^{16} is $(C_1$-$C_6)$alkyl, aryl or R^{17}-substituted aryl;

R^{18} is hydrogen or $(C_1$-$C_6)$alkyl; and

R^{19} is hydrogen, hydroxy or $(C_1$-$C_6)$alkoxy.

6. (Withdrawn) The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (V):



(V)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (V) or of the isomers thereof, or prodrugs of the compounds of Formula (V) or of the isomers, salts or solvates thereof, wherein, in Formula (V) above:

Ar^1 is aryl, R^{10}-substituted aryl or heteroaryl;

Ar^2 is aryl or R^4-substituted aryl;

Ar^3 is aryl or R^5-substituted aryl;

X and Y are independently selected from the group consisting of $-CH_2-$, -CH(lower alkyl)- and -C(dilower alkyl)-;

R is $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$ or $-O(CO)NR^6R^7$; R^1 is hydrogen, lower alkyl or aryl; or R and R^1 together are =O;

q is 0 or 1;

r is 0, 1 or 2;

m and n are independently 0, 1, 2, 3, 4 or 5; provided that the sum of m, n and q is 1, 2, 3, 4 or 5;

R^4 is 1-5 substituents independently selected from the group consisting of lower alkyl, $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^6$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2R^9$, $-COOR^6$, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $S(O)_{0-2}R^9$, $-O(CH_2)_{1-10}-COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, -(lower alkylene)$COOR^6$ and $-CH=CH-COOR^6$;

R^5 is 1-5 substituents independently selected from the group consisting of $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^6$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2R^9$, $-COOR^6$, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $S(O)_{0-2}R^9$, $-O(CH_2)_{1-10}-COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, $-CF_3$, -CN, $-NO_2$, halogen, -(lower alkylene)$COOR^6$ and $-CH=CH-COOR^6$;

R^6, R^7 and R^8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl;

R^9 is lower alkyl, aryl or aryl-substituted lower alkyl; and

R^{10} is 1-5 substituents independently selected from the group consisting of lower alkyl, $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^6$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2R^9$, $-COOR^6$, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $-S(O)_{0-2}R^9$, $-O(CH_2)_{1-10}-COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, $-CF_3$, -CN, $-NO_2$ and halogen.

7. (Withdrawn) The composition according to claim 1, where the at least one sterol absorption inhibitor is represented by Formula (VI):



(VI)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (VI) or of the isomers thereof, or prodrugs of the compounds of Formula (VI) or of the isomers, salts or solvates thereof, wherein in Formula (VI) above:

R_1 is

-CH-, -C(lower alkyl)-, -CF-, -C(OH)-, -C(C_6H_5)-, -C(C_6H_4-R_{15})-,

-N- or $-\overset{+}{N}O^-$;

R_2 and R_3 are independently selected from the group consisting of:
$-CH_2-$, -CH(lower alkyl)-, -C(di-lower alkyl)-, -CH=CH- and -C(lower alkyl)=CH-; or R_1 together with an adjacent R_2, or R_1 together with an adjacent R_3, form a -CH=CH- or a -CH=C(lower alkyl)- group;

u and v are independently 0, 1, 2 or 3, provided both are not zero; provided that when R_2 is -CH=CH- or -C(lower alkyl)=CH-, v is 1; provided that when R_3 is -CH=CH- or -C(lower alkyl)=CH-, u is 1; provided that when v is 2 or 3, the R_2's can be the same or different; and provided that when u is 2 or 3, the R_3's can be the same or different;

R_4 is selected from B-$(CH_2)_m$C(O)-, wherein m is 0, 1, 2, 3, 4 or 5;

B-$(CH_2)_q$-, wherein q is 0, 1, 2, 3, 4, 5 or 6;

B-$(CH_2)_e$-Z-$(CH_2)_r$-, wherein Z is -O-, -C(O)-, phenylene, -N(R_8)- or -S(O)$_{0-2}$-, e is 0, 1, 2, 3, 4 or 5 and r is 0, 1, 2, 3, 4 or 5, provided that the sum of e and r is 0, 1, 2, 3, 4, 5 or 6;

B-(C_2-C_6 alkenylene)-;

-(C_4-C_6 alkadienylene)-;

B-$(CH_2)_t$-Z-(C_2-C_6 alkenylene)-, wherein Z is as defined above, and wherein t is 0, 1, 2 or 3, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6;

B-$(CH_2)_f$-V-$(CH_2)_g$-, wherein V is C_3-C_6 cycloalkylene, f is 1, 2, 3, 4 or 5 and g is 0, 1, 2, 3, 4 or 5, provided that the sum of f and g is 1, 2, 3, 4, 5 or 6;

B-$(CH_2)_t$-V-(C_2-C_6 alkenylene)- or

B-(C_2-C_6 alkenylene)-V-$(CH_2)_t$-, wherein V and t are as defined above, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6; B-$(CH_2)_a$-Z-$(CH_2)_b$-V-$(CH_2)_d$-, wherein Z and V are as defined above and a, b and d are independently 0, 1, 2, 3, 4, 5 or 6, provided that the sum of a, b and d is 0, 1, 2, 3, 4, 5 or 6; or T-$(CH_2)_s$-, wherein T is cycloalkyl of 3-6 carbon atoms and s is 0, 1, 2, 3, 4, 5 or 6; or

R_1 and R_4 together form the group B-CH=C- ;

B is selected from indanyl, indenyl, naphthyl, tetrahydronaphthyl, heteroaryl or W-substituted heteroaryl, wherein heteroaryl is selected from the group consisting of pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, and for nitrogen-containing heteroaryls, the N-oxides thereof, or



W is 1 to 3 substituents independently selected from the group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxycarbonylalkoxy, (lower alkoxyimino)-lower alkyl, lower alkanedioyl, lower alkyl lower alkanedioyl, allyloxy, -CF_3, -OCF_3, benzyl, R7-benzyl, benzyloxy, R7-benzyloxy, phenoxy, R7-phenoxy, dioxolanyl, NO_2,-N(R8)(R9), N(R8)(R9)-lower alkylene-, N(R8)(R9)-lower alkylenyloxy-, OH, halogeno, -CN, -N_3, -NHC(O)OR_{10}, -NHC(O)R_{10}, $R_{11}O_2SNH$-, $(R_{11}O_2S)_2N$-, -S(O)$_2NH_2$, -S(O)$_{0-2}$R8, tert-butyldimethyl-silyloxymethyl, -C(O)R_{12}, -$COOR_{19}$, -CON(R8)(R9), -CH=CHC(O)R_{12}, -lower alkylene-C(O)R_{12}, R_{10}C(O)(lower alkylenyloxy)-, N(R8)(R9)C(O)(lower alkylenyloxy)- and  for substitution on ring carbon atoms, and the substituents on the substituted heteroaryl ring nitrogen atoms, when present, are selected from the group consisting of lower alkyl, lower alkoxy, -C(O)OR_{10}, -C(O)R_{10}, OH, N(R8)(R9)-lower alkylene-,N(R8)(R9)-lower alkylenyloxy-, -S(O)$_2NH_2$ and 2-(trimethylsilyl)-ethoxymethyl;

R7 is 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, -COOH, NO_2, -N(R8)(R9), OH, and halogeno;

R8 and R9 are independently selected from H or lower alkyl;

R_{10} is selected from lower alkyl, phenyl, R7-phenyl, benzyl or R7-benzyl;

R_{11} is selected from OH, lower alkyl, phenyl, benzyl, R7-phenyl or R7-benzyl;

R_{12} is selected from H, OH, alkoxy, phenoxy, benzyloxy,  , -N(R8)(R9), lower alkyl, phenyl or R7-phenyl;

R_{13} is selected from -O-, -CH_2-, -NH-, -N(lower alkyl)- or -NC(O)R_{19};

R_{15}, R_{16} and R_{17} are independently selected from the group consisting of H and the groups defined for W; or R_{15} is hydrogen and R_{16} and R_{17}, together with adjacent carbon atoms to which they are attached, form a dioxolanyl ring;

R_{19} is H, lower alkyl, phenyl or phenyl lower alkyl; and

R_{20} and R_{21} are independently selected from the group consisting of phenyl, W-substituted phenyl, naphthyl, W-substituted naphthyl, indanyl, indenyl, tetrahydronaphthyl, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzofused heteroaryl, W-substituted benzofused heteroaryl and cyclopropyl, wherein heteroaryl is as defined above.

8. (Withdrawn) The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (VIIA) or (VIIB):



(VIIA)

or



(VIIB)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formulae (VIIA) or (VIIB) or of the isomers thereof, or prodrugs of the compounds of Formulae (VIIA) or (VIIB) or of the isomers, salts or solvates thereof, wherein in Formulae (VIIA) and (VIIB) above:

A is -CH=CH-, -C≡C- or -$(CH_2)_p$- wherein p is 0, 1 or 2;

B is



B' is



D is -$(CH_2)_m$C(O)- or -$(CH_2)_q$- wherein m is 1, 2, 3 or 4 and q is 2, 3 or 4;

E is C_{10} to C_{20} alkyl or -C(O)-(C_9 to C_{19})-alkyl, wherein the alkyl is straight or branched, saturated or containing one or more double bonds;

R is hydrogen, C_1-C_{15} alkyl, straight or branched, saturated or containing one or more double bonds, or B-$(CH_2)_r$ -, wherein r is 0, 1, 2, or 3;

R_1, R_2, R_3, $R_{1'}$, $R_{2'}$, and $R_{3'}$ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, carboxy, NO_2, NH_2, OH, halogeno, lower alkylamino, dilower alkylamino, -NHC(O)OR_5, R_6O_2SNH- and -$S(O)_2NH_2$;

R_4 is



wherein n is 0, 1, 2 or 3;

R_5 is lower alkyl; and

R_6 is OH, lower alkyl, phenyl, benzyl or substituted phenyl wherein the substituents are 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, carboxy, NO_2, NH_2, OH, halogeno, lower alkylamino and dilower alkylamino.

9. (Withdrawn) The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (VIII):



(VIII)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (VIII) or of the isomers thereof, or prodrugs of the compounds of Formula (VIII) or of the isomers, salts or solvates thereof, wherein, in Formula (VIII) above,

R^{26} is H or OG^1;

G and G^1 are independently selected from the group consisting of

H,  ,  , 

and  ; provided that when R^{26} is H or OH, G is not H;

R, R^a and R^b are independently selected from the group consisting of H, -OH, halogeno, $-NH_2$, azido, (C_1-C_6)alkoxy(C_1-C_6)-alkoxy or -W-R^{30};

W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R^{31})-, -NH-C(O)-N(R^{31})- and -O-C(S)-N(R^{31})-;

R^2 and R^6 are independently selected from the group consisting of H, $(C_1$-$C_6)$alkyl, aryl and aryl$(C_1$-$C_6)$alkyl;

R^3, R^4, R^5, R^7, R^{3a} and R^{4a} are independently selected from the group consisting of H, $(C_1$-$C_6)$alkyl, aryl$(C_1$-$C_6)$alkyl, -C(O)$(C_1$-$C_6)$alkyl and -C(O)aryl;

R^{30} is selected from the group consisting of R^{32}-substituted T, R^{32}-substituted-T-$(C_1$-$C_6)$alkyl, R^{32}-substituted-$(C_2$-$C_4)$alkenyl, R^{32}-substituted-$(C_1$-$C_6)$alkyl, R^{32}-substituted-$(C_3$-$C_7)$cycloalkyl and R^{32}-substituted-$(C_3$-$C_7)$cycloalkyl$(C_1$-$C_6)$alkyl;

R^{31} is selected from the group consisting of H and $(C_1$-$C_4)$alkyl;

T is selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;

R^{32} is independently selected from 1-3 substituents independently selected from the group consisting of halogeno, $(C_1$-$C_4)$alkyl, -OH, phenoxy, $-CF_3$, $-NO_2$, $(C_1$-$C_4)$alkoxy, methylenedioxy, oxo, $(C_1$-$C_4)$alkylsulfanyl, $(C_1$-$C_4)$alkylsulfinyl, $(C_1$-$C_4)$alkylsulfonyl, $-N(CH_3)_2$, -C(O)-NH$(C_1$-$C_4)$alkyl, -C(O)-N$((C_1$-$C_4)$alkyl$)_2$, -C(O)-$(C_1$-$C_4)$alkyl, -C(O)-$(C_1$-$C_4)$alkoxy and pyrrolidinylcarbonyl; or R^{32} is a covalent bond and R^{31}, the nitrogen to which it is attached and R^{32} form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a $(C_1$-$C_4)$alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;

Ar^1 is aryl or R^{10}-substituted aryl;

Ar^2 is aryl or R^{11}-substituted aryl;

Q is a bond or, with the 3-position ring carbon of the azetidinone,



forms the spiro group ; and

R^1 is selected from the group consisting of

$-(CH_2)_q-$, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;

$-(CH_2)_e-E-(CH_2)_r-$, wherein E is -O-, -C(O)-, phenylene, $-NR^{22}-$ or $-S(O)_{0-2}-$, e is 0-5 and r is 0-5, provided that the sum of e and r is 1-6;

$-(C_2-C_6)$alkenylene-; and

$-(CH_2)_f-V-(CH_2)_g-$, wherein V is C_3-C_6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;

R^{12} is

-CH-, $-C(C_1-C_6$ alkyl)-, -CF-, -C(OH)-, $-C(C_6H_4-R^{23})-$, -N-, or $-{}^{+}NO^{-}$;

R^{13} and R^{14} are independently selected from the group consisting of $-CH_2-$, $-CH(C_1-C_6$ alkyl)-, -C(di-(C_1-C_6) alkyl), -CH=CH- and $-C(C_1-C_6$ alkyl)=CH-; or R^{12} together with an adjacent R^{13}, or R^{12} together with an adjacent R^{14}, form a -CH=CH- or a $-CH=C(C_1-C_6$ alkyl)- group;

a and b are independently 0, 1, 2 or 3, provided both are not zero;

provided that when R^{13} is -CH=CH- or $-C(C_1-C_6$ alkyl)=CH-, a is 1;

provided that when R^{14} is -CH=CH- or $-C(C_1-C_6$ alkyl)=CH-, b is 1;

provided that when a is 2 or 3, the R^{13}'s can be the same or different; and

provided that when b is 2 or 3, the R^{14}'s can be the same or different;

and when Q is a bond, R^1 also can be:



M is -O-, -S-, -S(O)- or -$S(O)_2$-;

X, Y and Z are independently selected from the group consisting of -CH_2-, -CH(C_1-C_6)alkyl- and -C(di-(C_1-C_6)alkyl);

R^{10} and R^{11} are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C_1-C_6)alkyl, -OR^{19}, -$O(CO)R^{19}$, -$O(CO)OR^{21}$, -$O(CH_2)_{1-5}OR^{19}$, -$O(CO)NR^{19}R^{20}$, -$NR^{19}R^{20}$, -$NR^{19}(CO)R^{20}$, -$NR^{19}(CO)OR^{21}$, -$NR^{19}(CO)NR^{20}R^{25}$, -$NR^{19}SO_2R^{21}$, -$COOR^{19}$, -$CONR^{19}R^{20}$, -COR^{19}, -$SO_2NR^{19}R^{20}$, $S(O)_{0-2}R^{21}$, -$O(CH_2)_{1-10}$-$COOR^{19}$, -$O(CH_2)_{1-10}CONR^{19}R^{20}$, -($C_1$-$C_6$ alkylene)-$COOR^{19}$, -CH=CH-$COOR^{19}$, -CF_3, -CN, -NO_2 and halogen;

R^{15} and R^{17} are independently selected from the group consisting of -OR^{19}, -$O(CO)R^{19}$, -$O(CO)OR^{21}$ and -$O(CO)NR^{19}R^{20}$;

R^{16} and R^{18} are independently selected from the group consisting of H, (C_1-C_6)alkyl and aryl; or R^{15} and R^{16} together are =O, or R^{17} and R^{18} together are =O;

d is 1, 2 or 3;

h is 0, 1, 2, 3 or 4;

s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4;

provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6;

provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;

v is 0 or 1;

j and k are independently 1-5, provided that the sum of j, k and v is 1-5;

and when Q is a bond and R^1 is $-X_j-(C)_v-Y_k-S(O)_{0-2}-$ (with R^{15} and R^{16}), Ar^1 can also be pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;

R^{19} and R^{20} are independently selected from the group consisting of H, $(C_1\text{-}C_6)$alkyl, aryl and aryl-substituted $(C_1\text{-}C_6)$alkyl;

R^{21} is $(C_1\text{-}C_6)$alkyl, aryl or R^{24}-substituted aryl;

R^{22} is H, $(C_1\text{-}C_6)$alkyl, aryl $(C_1\text{-}C_6)$alkyl, $-C(O)R^{19}$ or $-COOR^{19}$;

R^{23} and R^{24} are independently 1-3 groups independently selected from the group consisting of H, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, -COOH, NO_2, $-NR^{19}R^{20}$, -OH and halogeno; and

R^{25} is H, -OH or $(C_1\text{-}C_6)$alkoxy.

10. (Withdrawn) The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (IX):



(IX)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (IX) or of the isomers thereof, or prodrugs of the compounds of Formula (IX) or of the isomers, salts or solvates thereof, wherein, in Formula (IX) above,

R^{26} is selected from the group consisting of:

a) OH;

b) OCH_3;

c) fluorine and

d) chlorine;

R^1 is selected from the group consisting of

H,  ,  ,  ,  -SO_3H; natural and unnatural amino acids;

R, R^a and R^b are independently selected from the group consisting of H, -OH, halogeno, $-NH_2$, azido, (C_1-C_6)alkoxy(C_1-C_6)-alkoxy and -W-R^{30};

W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R^{31})-, -NH-C(O)-N(R^{31})- and -O-C(S)-N(R^{31})-;

R^2 and R^6 are independently selected from the group consisting of H, (C_1-C_6)alkyl, aryl and aryl(C_1-C_6)alkyl;

R^3, R^4, R^5, R^7, R^{3a} and R^{4a} are independently selected from the group consisting of H, (C_1-C_6)alkyl, aryl(C_1-C_6)alkyl, -C(O)(C_1-C_6)alkyl and -C(O)aryl;

R^{30} is independently selected form the group consisting of R^{32}-substituted T, R^{32}-substituted-T-(C_1-C_6)alkyl, R^{32}-substituted-(C_2-C_4)alkenyl, R^{32}-substituted-(C_1-C_6)alkyl, R^{32}-substituted-(C_3-C_7)cycloalkyl and R^{32}-substituted-(C_3-C_7)cycloalkyl(C_1-C_6)alkyl;

R^{31} is independently selected from the group consisting of H and (C_1-C_4)alkyl;

T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;

R^{32} is independently selected from 1-3 substituents independently selected from the group consisting of H, halogeno, (C_1-C_4)alkyl, -OH, phenoxy, -CF_3, -NO_2, (C_1-C_4)alkoxy, methylenedioxy, oxo, (C_1-C_4)alkylsulfanyl, (C_1-C_4)alkylsulfinyl, (C_1-C_4)alkylsulfonyl, -$N(CH_3)_2$, -C(O)-NH(C_1-C_4)alkyl, -C(O)-N((C_1-C_4)alkyl)$_2$, -C(O)-(C_1-C_4)alkyl, -C(O)-(C_1-C_4)alkoxy and pyrrolidinylcarbonyl; or R^{32} is a covalent bond and R^{31}, the nitrogen to which it is attached and R^{32} form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a (C_1-C_4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;

Ar^1 is aryl, R^{10}-substituted aryl; pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;

Ar^2 is aryl or R^{11}-substituted aryl;

Q is -$(CH_2)_q$-, wherein q is 2-6, or, with the 3-position ring carbon of the azetidinone,

forms the spiro group  ;

R^{12} is



R^{13} and R^{14} are independently selected from the group consisting of -CH_2-, -CH(C_1-C_6 alkyl)-, -C(di-(C_1-C_6) alkyl), -CH=CH- and -C(C_1-C_6 alkyl)=CH-; or R^{12} together with an adjacent R^{13}, or R^{12} together with an adjacent R^{14}, form a

-CH=CH- or a -CH=C(C_1-C_6 alkyl)- group;

a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R^{13} is -CH=CH- or -C(C_1-C_6 alkyl)=CH-, a is 1; provided that when R^{14} is -CH=CH- or -C(C_1-C_6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R^{13}'s can be the same or different; and provided that when b is 2 or 3, the R^{14}'s can be the same or different;

R^{10} and R^{11} are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C_1-C_6)alkyl, -OR^{19}, -$O(CO)R^{19}$, -$O(CO)OR^{21}$, -$O(CH_2)_{1-5}OR^{19}$, -$O(CO)NR^{19}R^{20}$, -$NR^{19}R^{20}$, -$NR^{19}(CO)R^{20}$, -$NR^{19}(CO)OR^{21}$, -$NR^{19}(CO)NR^{20}R^{25}$, -$NR^{19}SO_2R^{21}$, -$COOR^{19}$, -$CONR^{19}R^{20}$, -COR^{19}, -$SO_2NR^{19}R^{20}$, -$S(O)_{0-2}R^{21}$, -$O(CH_2)_{1-10}$-$COOR^{19}$, -$O(CH_2)_{1-10}CONR^{19}R^{20}$, -($C_1$-$C_6$ alkylene)-$COOR^{19}$, -CH=CH-$COOR^{19}$, -CF_3, -CN, -NO_2 and halogen;

R^{19} and R^{20} are independently selected from the group consisting of H, (C_1-C_6)alkyl, aryl and aryl-substituted (C_1-C_6)alkyl;

R^{21} is (C_1-C_6)alkyl, aryl or R^{24}-substituted aryl;

R^{22} is H, (C_1-C_6)alkyl, aryl (C_1-C_6)alkyl, -$C(O)R^{19}$ or -$COOR^{19}$;

R^{23} and R^{24} are independently 1-3 groups independently selected from the group consisting of H, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, -COOH, NO_2, -$NR^{19}R^{20}$, -OH and halogeno; and

R^{25} is H, -OH or (C_1-C_6)alkoxy.

11. (Canceled).

12. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is an anti-coagulant.

13. (Withdrawn) The composition according to claim 12, wherein the anti-coagulant is selected from the group consisting of argatroban, bivalirudin, dalteparin sodium, desirudin, dicumarol, lyapolate sodium, nafamostat mesylate, phenprocoumon, tinzaparin sodium, warfarin sodium and combinations thereof.

14. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is an anti-thrombotic agent.

15. (Withdrawn) The composition according to claim 14, wherein the antithrombotic agent is selected from the group consisting of anagrelide hydrochloride, bivalirudin, cilostazol, dalteparin sodium, danaparoid sodium, dazoxiben hydrochloride, efegatran sulfate, enoxaparin sodium, fluretofen, ifetroban, ifetroban sodium, lamifiban, lotrafiban hydrochloride, napsagatran, orbofiban acetate, roxifiban acetate, sibrafiban, tinzaparin sodium, trifenagrel, abciximab, zolimomab aritox and combinations thereof.

16. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is a fibrinogen receptor antagonist.

17. (Withdrawn) The composition according to claim 16, wherein the fibrinogen receptor antagonist is selected from the group consisting of roxifiban acetate, fradafiban, orbofiban, lotrafiban hydrochloride, tirofiban, xemilofiban, monoclonal antibody 7E3, sibrafiban and combinations thereof.

18-20. (Canceled).

21. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is a platelet aggregation inhibitor.

22. (Withdrawn) The composition according to claim 21, wherein the platelet aggregation inhibitor is selected from the group consisting of acadesine, beraprost, beraprost sodium, ciprostene calcium, itazigrel, lifarizine, lotrafiban hydrochloride, orbofiban acetate, oxagrelate, fradafiban, orbofiban, tirofiban, xemilofiban and combinations thereof.

23. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is a hemorrheologic agent.

24. (Withdrawn) The composition according to claim 23, wherein the hemorrheologic agent is pentoxifylline.

25. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is a lipoprotein associated coagulation inhibitor.

26. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is a Factor Xa inhibitor.

27. (Withdrawn) The composition according to claim 26, wherein the Factor Xa inhibitor is selected from the group consisting of disubstituted pyrazolines, disubstituted triazolines, substituted n-[(aminoiminomethyl)phenyl] propylamides, substituted n-[(aminomethyl)phenyl] propylamides, tissue factor pathway inhibitor (TFPI), low molecular weight heparins, heparinoids, benzimidazolines, benzoxazolinones, benzopiperazinones, indanones, dibasic (amidinoaryl) propanoic acid derivatives, amidinophenyl-pyrrolidines, amidinophenyl-pyrrolines, amidinophenyl-isoxazolidines, amidinoindoles, amidinoazoles, bis-arlysulfonylaminobenzamide

derivatives, peptidic Factor Xa inhibitors and combinations thereof.

28. (Withdrawn) The composition according to claim 1, wherein the at least one blood modifier is a low molecular weight heparin.

29. (Withdrawn) The composition according to claim 28, wherein the low molecular weight heparin is selected from the group of enoxaparin, nardroparin, dalteparin, certroparin, parnaparin, reviparin, tinzaparin and combinations thereof.

30. (Withdrawn) The composition according to claim 1, wherein the at least one blood modifier is a heparinoid.

31. (Withdrawn) The composition according to claim 30, wherein the heparinoid is danaparoid.

32. (Withdrawn) The composition according to claim 11, wherein the at least one blood modifier is a Factor VIIa inhibitor.

33. (Withdrawn) The composition according to claim 32, wherein the Factor VIIa Inhibitor is selected from the group consisting of 4H-31-benzoxazin-4-ones, 4H-3,1-benzoxazin-4-thiones, quinazolin-4-ones, quinazolin-4-thiones, benzothiazin-4-ones, imidazolyl-boronic acid-derived peptide analogues TFPI-derived peptides and combinations thereof.

34. (Withdrawn) The composition according to claim 32, wherein the Factor VIIa Inhibitor is selected from the group consisting of naphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxo-pyrrolidin-3-(S)-yl} amide trifluoroacetate, dibenzofuran-2-sulfonic acid {1-[3-(aminomethyl)-benzyl]-5-oxo-pyrrolidin-3-yl}-amide, tolulene-4-sulfonic acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxo-pyrrolidin-3-

(S)-yl}-amide trifluoroacetate, 3,4-dihydro-1H-isoquinoline-2-sulfonic acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxo-pyrrolin-3-(S)-yl}-amide trifluoroacetate and combinations thereof.

35. (Original) The composition according to claim 1, further comprising at least one cholesterol biosynthesis inhibitor.

36. (Original) The composition according to claim 35, wherein the at least one cholesterol biosynthesis inhibitor comprises at least one HMG CoA reductase inhibitor.

37. (Original) The composition according to claim 36, wherein the at least one HMG CoA reductase inhibitor is simvastatin.

38. (Withdrawn) The composition according to claim 1, further comprising at least one bile acid sequestrant.

39. (Withdrawn) The composition according to claim 1, further comprising at least one low-density lipoprotein receptor activator.

40. (Withdrawn) The composition according to claim 1, further comprising at least one Omega 3 fatty acid.

41. (Withdrawn) The composition according to claim 1, further comprising at least one natural water soluble fiber.

42. (Original) The composition according to claim 1, further comprising at least one antioxidant or vitamin.

43. (Canceled).

44. (Canceled).

45. (Previously Presented) A pharmaceutical composition for the treatment of vascular conditions, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising a therapeutically effective amount of the composition of claim 1 and a pharmaceutically acceptable carrier.

46. (Withdrawn) A method of treating or preventing vascular conditions, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising the step of administering to a mammal in need of such treatment:

(a) an effective amount of at least one sterol absorption inhibitor or pharmaceutically acceptable salt or solvate thereof or prodrug of the at least one sterol absorption inhibitor or of the salt or solvate thereof; and

(b) an effective amount of at least one blood modifier for vascular conditions which is different from the sterol absorption inhibitor.

47. (Currently Amended) A therapeutic combination comprising:

(a) a first amount of 0.1 to 1000 milligrams of a sterol absorption represented by Formula (II):

Response Under 37 CFR 1.116
Expedited Procedure
Examining Group 1617
Application No. 10/056,680
Amendment Dated: January 9, 2007
Reply to Final Office Action of July 11, 2006



(II)

or pharmaceutically acceptable salts or solvates thereof; ~~at least one sterol absorption inhibitor represented by Formula (I):~~



~~(I)~~

~~or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (I) or of the isomers thereof, wherein:~~

~~Ar^1 and Ar^2 are independently selected from the group consisting of aryl and R^4-substituted aryl;~~

~~Ar^3 is aryl or R^5-substituted aryl;~~

~~X, Y and Z are independently selected from the group consisting of $-CH_2-$, -CH(lower alkyl)- and -C(dilower alkyl)-;~~

~~R and R^3 are independently selected from the group consisting of $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$ and $-O(CO)NR^6R^7$;~~

~~R^1 and R^3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;~~

~~q is 0 or 1;~~

~~r is 0 or 1;~~

~~m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;~~

~~R^4 is 1-5 substituents independently selected from the group consisting of lower alkyl, $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^6$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2R^9$, $-COOR^6$, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $-S(O)_{0-2}R^9$, $-O(CH_2)_{1-10}COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, (lower alkylene)$COOR^6$, $-CH=CHCOOR^6$, $-CF_3$, $-CN$, $-NO_2$ and halogen;~~

~~R^5 is 1-5 substituents independently selected from the group consisting of $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^6$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2R^9$, $-COOR^6$, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $-S(O)_{0-2}R^9$, $-O(CH_2)_{1-10}COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, (lower alkylene)$COOR^6$ and $-CH=CHCOOR^6$;~~

~~R^6, R^7 and R^8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and~~

~~R^9 is lower alkyl, aryl or aryl-substituted lower alkyl;~~ and

(b) a second amount of 1 to 1000 milligrams of aspirin,

wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment of vascular conditions, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.

48. (Withdrawn) A method of treating or preventing vascular conditions, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising the step of administering to a mammal in need of such treatment an effective amount of the therapeutic combination of claim 47.